Xin Lang Cai Jing·2025-09-24 10:23Core Insights - Fosun Pharma's subsidiary, Fosun Kairui (Shanghai) Biotechnology Co., Ltd., has had its second CAR-T product, Brexucabtagene Autoleucel (code name FKC889), accepted for drug registration by the National Medical Products Administration (NMPA) [1] - The indication for this application is for adult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL) [1] Company Summary - Fosun Pharma is advancing its CAR-T product pipeline with the acceptance of Brexucabtagene Autoleucel for regulatory review [1] - The focus on treating relapsed or refractory ALL highlights the company's commitment to addressing unmet medical needs in oncology [1] Industry Summary - The CAR-T therapy market continues to expand, with increasing regulatory approvals for innovative treatments targeting specific cancer types [1] - The acceptance of new CAR-T products indicates a growing trend in the biopharmaceutical industry towards personalized medicine and advanced therapies for complex diseases [1]